Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Wittrup, Karl Dane"'
Autor:
Maass, Katie F., Kulkarni, Chethana, Quadir, Mohiuddin A., Hammond, Paula T., Betts, Alison M., Wittrup, Karl Dane *
Publikováno v:
In Journal of Pharmaceutical Sciences December 2015 104(12):4409-4416
Autor:
Rhoden, John J., Wittrup, Karl Dane *
Publikováno v:
In Journal of Pharmaceutical Sciences February 2012 101(2):860-867
Autor:
Wittrup, Karl Dane
The baker's yeast Saccharomyces cerevisiae is potentially a very useful host for the production of pharmaceutical proteins by recombinant DNA technology. One requirement for efficient overproduction of a foreign protein in yeast is a stable recombina
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Szeto, Gregory L., Overwijk, Willem W., Tzeng, Alice, Kauke, Monique Jacqueline, Zhu, Eric Franklin, Moynihan, Kelly Dare, Opel, Cary Francis, Yang, Nicole Jie Yeon, Mehta, Naveen, Irvine, Darrell J, Wittrup, Karl Dane
Publikováno v:
Elsevier
Numerous synergistic cancer immunotherapy combinations have been identified, but the effects of relative dose timing are rarely considered. In established syngeneic mouse tumor models, we found that staggering interferon-α (IFNα) administration aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________88::c775df62701f98c2d930297ab4c2d0c2
https://orcid.org/0000-0001-7316-6923
https://orcid.org/0000-0001-7316-6923
Autor:
Xu, Hong, Guo, Hong-fen, Lee, Sang-gyu, Punzalan, Blesida, Chalasani, Sandhya, Jungbluth, Achim, O’Donoghue, Joseph, Cheal, Sarah M., Fung, Edward K., Zanzonico, Pat B., Carrasquillo, Jorge A., Smith-Jones, Peter M., Cheung, Nai-Kong V., Larson, Steven M., Wittrup, Karl Dane
Publikováno v:
Springer Berlin Heidelberg
Purpose: GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________88::85c198e06bbf99ab34fecc86158329c8
http://hdl.handle.net/1721.1/104432
http://hdl.handle.net/1721.1/104432
Publikováno v:
PMC
Stimulation of patients' immune systems for the treatment of solid tumors is an emerging therapeutic paradigm. The use of enriched autologous T cells for adoptive cell therapy or vaccination with antigen-loaded dendritic cells have shown clinical eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________88::8243dc77119a2618c11a3a782000de8b
https://orcid.org/0000-0003-2398-5896
https://orcid.org/0000-0003-2398-5896
Autor:
Yao, Xiaosai, Labelle, Myriam, Lamb, Carla R., Dugan, John M., Williamson, Christina A., Spencer, Donna R., Christ, Kimberly R., Keating, Ryan O., Lee, W. David, Paradis, Glenn A., Begum, Shahinoor, Wittrup, Karl Dane, Hynes, Richard O
Publikováno v:
PMC
Many targets have been identified in solid tumors for antibody therapy but it is less clear what surface antigens may be most commonly expressed on disseminated tumor cells. Using malignant pleural effusions as a source of disseminated tumor cells, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::28a09442a3cfd4c7db4038a5e9d141e3
https://europepmc.org/articles/PMC4107365/
https://europepmc.org/articles/PMC4107365/
Publikováno v:
PMC
Targeted endocytic uptake is a first step toward tissue-specific cytoplasmic macromolecular delivery; however, inefficient escape from the endolysosomal compartment makes this generally impractical at present. We report here a targeted cytolysin appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b5b1f51ac49d6689f38e532e3241f9
https://orcid.org/0000-0003-2398-5896
https://orcid.org/0000-0003-2398-5896